Home Contact Us Site Index Search
	Last Price Change Date Time Delay ASX: 1.25 0.05 9 July 08 12:20 20 min NASDAQ: 1.26 0.21 8 July 08 15:57 20 min

PI-88 Progen's phase 3 anti-angiogenic compound EPIGENETICS Progen now has a large platform of preclinical epigenetic assets PIPELINE Progen's cancer drug development program is focused on improving health outcomes for cancer patients

In The News... 2 July 2008 Progen Spins-Out Manufacturing Business 2 June 2008 Vice President of Research and Development Resignation 30 May 2008 Progen Presents on Epigenetics Platform at AACR 27 May 2008 Progen Corporate Presentation 19 May 2008 Progen Response to Media Coverage 15 May 2008 Progen Resumes Phase 1 Development of Anti-Cancer Agent PG11047 14 April 2008 Progen Presents PG500 Series at AACR Annual Conference San Diego Click here for a copy of the poster 27 March 2008 Progen Restructures Manufacturing and Drug Discovery Divisions 19 March 2008 Progen Market Update - Response to Media Coverage 11 March 2008 Progen Announces Commencement of Global Phase 3 Trial 4 March 2008 Progen Expands Board of Directors 18 February 2008 Progen Half Yearly Results 13 February 2008 Phase 2 Preliminary Prostate Data 7 February 2008 Progen Closes Acquisition of Cellgate Inc 5 February 2008 Progen's Acquisition of Cellgate Teleconference Click here to listen 4 February 2008 Cellgate Acquisition Presentation to Accompany Investor Teleconference 4 February 2008 Investor Teleconference dial-in details 4 February 2008 Cellgate Acquisition 1 February 2008 Financial Update More news...

Life Sciences Division

© Progen Pharmaceuticals Limited | Privacy Policy | Disclaimer